Skip to main
PEN

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 20%
Buy 13%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra is a market leader in the medical device industry, with a strong portfolio of innovative products that are aimed at improving treatment outcomes for patients with vascular diseases. They have a diverse product portfolio and continue to grow and expand internationally. While there is some overlap with Boston Scientific, we do not anticipate antitrust issues and believe the premium price of the acquisition is warranted due to Penumbra's strong growth and profitability. However, there are potential risks such as ongoing litigation and integration issues with M&A activity.

Bears say

Penumbra is a growing company in the thrombectomy space, with strong revenue growth and high operating margins. However, the recent acquisition deal by Boston Scientific raises concerns about competitive pressures and the potential for penetration by larger, well-established players with greater resources. Additionally, risks such as regulatory approvals and changes in reimbursement could negatively impact the company's performance. There is also concern about potential challenges in competing against these established players in the marketplace.

Penumbra (PEN) has been analyzed by 15 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 13% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Hold based on their latest research and market trends.

According to 15 analysts, Penumbra (PEN) has a Hold consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $358.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $358.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.